Genocea Presents New Data Demonstrating the Power and Versatility of its ATLAS™ Antigen Identification Platform at SITC 20...
November 07 2017 - 8:05AM
- ATLAS continues to demonstrate superiority to
in silico methods of neoantigen identification in multiple tumor
types - - ATLAS also identifies unique tumor-associated antigen
response signatures in patients with lung and colorectal cancers
-
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical
company developing neoantigen cancer vaccines, today provided
details on its three poster presentations at the upcoming Society
for Immunotherapy of Cancer (SITC) 32nd Annual Meeting taking place
November 8 to 12, 2017 at the Gaylord National Hotel &
Convention Center in National Harbor, Maryland. The posters, all of
which will be presented on Saturday, November 11, highlight the
power of Genocea’s proprietary antigen identification system ATLAS™
to identify and profile CD4+ and CD8+ T cell responses to
neoantigens and tumor-associated antigens (TAAs) for potential use
in cancer vaccines and as non-invasive biomarkers.
"These data demonstrate the versatility of ATLAS and support our
use of the technology in the development of next-generation
neoantigen cancer vaccines," said Jessica Baker Flechtner, Ph.D.,
chief scientific officer at Genocea. "With our first personalized
vaccine candidate expected to enter the clinic in 2018, we are
excited that ATLAS continues to demonstrate superiority to in
silico methods of neoantigen identification and believe that our
ability to identify true neoantigens will be key to developing more
effective immunotherapies. We are also eager to further explore,
through partnerships, the potential of ATLAS in the identification
of novel tumor-associated antigens for biomarkers and common
antigen cancer vaccines.”
Poster #430: “Neoantigen identification using ATLAS™
across multiple tumor types highlights limitations of prediction
algorithms,” will be presented during the session on
Personalized Vaccines and Technologies/Personalized Medicine.
Highlights include:
- ATLAS identified true neoantigens of CD8+ and CD4+ T cells,
independent of patient HLA type, across a broad cohort of patients
with different tumor types, including those with high or low
mutational burden
- Cancer types studied include renal cell carcinoma, and
prostate, colorectal, pancreatic, and non-small cell lung
cancers
- Only 4% of ATLAS-identified neoantigens were predicted by
NetMHCpan (a widely used in silico tool for neoantigen
prediction)
- 88% of neoantigens that were predicted by NetMHCpan and
confirmed by ATLAS were inhibitory and thus questionable for
inclusion in cancer vaccines
- The identification of activating and inhibitory
neoantigens for CD8+ and CD4+ T cells should better enable
neoantigen vaccines to stimulate a protective immune
response
Poster #8: “T cell response profiling in colorectal
carcinoma patients reveals an enrichment in responses to specific
tumor-associated antigens,” will be presented during the
session on Biomarkers and Immune Monitoring. Highlights
include:
- Tumor stage at time of diagnosis is considered to be the most
important predictor of survival in colorectal cancer (CRC)
patients; tumor-associated antigen (TAA)-specific responses in
peripheral blood can be detected using ATLAS
- ATLAS identified T cell responses to a subset of TAAs in
individuals with pre-malignant adenomatous polyps that were similar
to those in CRC patients and distinguishable from healthy
individuals
- Three TAAs that were most frequently identified in this cohort
of patients were not aligned with those previously investigated as
therapeutic vaccines
- Data support investigation of this new set of TAAs as
antigens for a novel vaccine to complement personalized cancer
vaccine approaches
- Data also support potential development of a
non-invasive blood-based assay for early detection and diagnosis of
CRC
Poster #28 entitled “Profiling of T cell responses to
tumor-associated antigens in lung cancer patients treated with
checkpoint inhibitors,” will be presented during the
session on Biomarkers and Immune Monitoring. Highlights
include:
- ATLAS identified both stimulatory and inhibitory CD8+ and CD4+
T cell responses to TAAs in lung cancer patients treated with
checkpoint inhibitors
- ATLAS confirmed two TAAs that elicited more frequent responses
than NY-ESO-1, MUC1, and MAGEA3, three TAAs that have been studied
previously in clinical trials as vaccine antigens for lung cancer
patients
- Data support investigation of these TAAs as antigens to
include in a common-antigen immunotherapy for lung
cancer
- T cell response profiles associating with effective treatment
with checkpoint blockade are under investigation
About Genocea Biosciences, Inc.Genocea is
harnessing the power of T cell immunity to develop potentially
life-changing vaccines and immunotherapies. While traditional
immunotherapy discovery methods have largely used predictive
methods to propose T cell targets, or antigens, Genocea has
developed ATLAS™, its proprietary technology platform, to identify
clinically relevant antigens of T cells based on actual human
immune responses. Genocea is using ATLAS in immuno-oncology
applications to develop neoantigen cancer vaccines while also
exploring partnership opportunities for general cancer vaccines and
a vaccine targeting cancers caused by Epstein-Barr Virus. Genocea
expects to begin clinical development of its first neoantigen
cancer vaccine, GEN-009, in 2018. Genocea is exploring strategic
alternatives for GEN-003, its Phase 3-ready immunotherapy candidate
for the treatment of genital herpes. For more information, please
visit www.genocea.com.
Forward-Looking StatementsStatements herein
relating to future business performance, conditions or strategies
and other financial and business matters, including expectations
regarding clinical developments, are forward-looking statements
within the meaning of the Private Securities Litigation Reform Act.
Genocea cautions that these forward-looking statements are subject
to numerous assumptions, risks, and uncertainties that change over
time. Factors that may cause actual results to differ materially
from the results discussed in the forward-looking statements or
historical experience include risks and uncertainties, including
Genocea's ability to progress any product candidates in preclinical
or clinical trials; the ability of ATLAS to identify promising
oncology vaccine and immunotherapy product candidates; the scope,
rate and progress of its preclinical studies and clinical trials
and other research and development activities; anticipated clinical
trial results; anticipated timing for initiation of new clinical
trials; current results may not be predictive of future results;
even if the data from preclinical studies or clinical trials is
positive, regulatory authorities may require additional studies for
approval and the product may not prove to be safe and efficacious;
Genocea's ability to enter into future collaborations with industry
partners and the government and the terms, timing and success of
any such collaboration; risks associated with the manufacture and
supply of clinical and commercial product; the cost of filing,
prosecuting, defending and enforcing any patent claims and other
intellectual property rights; Genocea's ability to obtain rights to
technology; competition for clinical resources and patient
enrollment from drug candidates in development by other companies
with greater resources and visibility; the rate of cash utilized by
Genocea in its business and the period for which existing cash will
be able to fund such operation; Genocea's ability to obtain
adequate financing in the future to continue its clinical programs
through product licensing, co-promotional arrangements, public or
private equity or debt financing or otherwise; general business
conditions; competition; business abilities and judgment of
personnel; the availability of qualified personnel and other
factors set forth under "Risk Factors" in Genocea's Quarterly
Report on Form 10-Q for the fiscal quarter ended September 30, 2017
and other filings with the Securities and Exchange Commission (the
"SEC"). Further information on the factors and risks that could
affect Genocea's business, financial conditions, and results of
operations is contained in Genocea's filings with the SEC, which
are available at www.sec.gov. These forward-looking statements
speak only as of the date of this press release and Genocea assumes
no duty to update forward-looking statements.
For
media: |
|
For
investors: |
Jennifer LaVin |
|
Jonathan Poole |
207-360-0473 |
|
617-876-8191 |
jennifer.lavin@genocea.com |
|
jonathan.poole@genocea.com |
Genocea Biosciences (NASDAQ:GNCA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genocea Biosciences (NASDAQ:GNCA)
Historical Stock Chart
From Apr 2023 to Apr 2024